February 17, 2004Circulation
Usefulness of B-Type Natriuretic Peptide Assay in the Assessment of Symptomatic State in Hypertrophic Cardiomyopathy
Key result
Plasma BNP levels were significantly associated with NYHA functional class in hypertrophic cardiomyopathy (P<0.001), with mean levels of 136, 338, and 481 pg/mL for classes I, II, and III/IV.
Why the study?
Does plasma B-type natriuretic peptide (BNP) assay correlate with symptom severity in patients with hypertrophic cardiomyopathy?
Population
107 consecutive patients with hypertrophic cardiomyopathy (HCM)
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Supports BNP for symptom severity assessment in HCM; leaves open incremental value beyond age and wall thickness.
Study Design
Type
Observational (n=107)
Structured PICO
Does plasma B-type natriuretic peptide (BNP) assay correlate with symptom severity in patients with hypertrophic cardiomyopathy?
P
Population
107 consecutive patients with hypertrophic cardiomyopathy (HCM)
I
Intervention
Plasma B-type natriuretic peptide (BNP) assay
O
Outcome
Relationship to magnitude of functional limitation, assessed by New York Heart Association (NYHA) functional classsurrogate
Main Result
p-value: p=<0.001
Plasma BNP is independently related to heart failure symptoms in HCM, but its clinical utility is limited by value overlap and confounding by age and wall thickness.
Limitations
- Considerable overlap in values between categories of heart failure severity
- Confounding variables of left ventricular wall thickness and age
Cite This Study
Maron et al. (2004) conducted an observational in Hypertrophic cardiomyopathy (n=107). Plasma B-type natriuretic peptide (BNP) assay was evaluated on Relationship between BNP and magnitude of functional limitation (NYHA class) (p=<0.001). Plasma BNP levels were significantly associated with NYHA functional class in hypertrophic cardiomyopathy (P<0.001), with mean levels of 136, 338, and 481 pg/mL for classes I, II, and III/IV.